¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antismooth muscle antibody"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® muscle ÇÑ±Û ±ÙÀ°
¼³¸í   
  ÀǽÄÀÇ Á¶Àý¿©ºÎ¿¡ µû¶ó ¼öÀDZÙ(ÀǽĿ¡ ÀÇÇØ¼­ Á¶ÀýÀÌ °¡´ÉÇÑ ±ÙÀ°: ¿¹¸¦ µé¾î ´Ù¸®, ÆÈ, ¾ó±¼±ÙÀ° µî)°ú ºÒ¼öÀDZÙ(Àǽİú ¹«°üÇϰԠÁ¶ÀýÇÏÁö ¾Ê¾Æµµ ¿òÁ÷À̴ ±ÙÀ°: ¿¹¸¦ µé¾î ½ÉÀå±Ù, ¼ÒÈ­±â°ü¿¡ ºÐÆ÷Çϴ ±ÙÀ° µî)À¸·Î ³ª´©¾îÁú ¼ö ÀÖÀ¸¸ç, ¶ÇÇÑ ½ÉÀå±ÙÀÌ µû·Î Á¸ÀçÇÑ´Ù.
¿µ¹® muscle biopsy ÇÑ±Û ±ÙÀ°»ý°Ë
¼³¸í   
  »ýü³»¿¡¼­ ±ÙÀ°¿¡ ´ëÇÑ Áúº´ÀÇ °¨º°Áø´ÜÀ» À§Çؼ­ ½Ç½ÃÇϴ °Ë»ç¹ý. ¹æ¹ýÀº º´ÅͰ¡ Àִ ºÎÀ§³ª È¤Àº ¾ø¾îµµ Å©°Ô È°µ¿¿¡ ÁöÀåÀÌ ¾ø´Â ±ÙÀ°ºÎÀ§ÀÇ Á¶Á÷À» ¶¼¾î Çö¹Ì°æÀûÀ¸·Î °Ë»çÇÑ´Ù. ¿¹¸¦ µé¾î ½Å°æÁ¶Á÷ÀÇ ÀÌ»óÀ¸·Î ÀÎÇÑ ±ÙÀ°º´ÅÍÀÇ °æ¿ì, ±ÙÀ°»ý°ËÀ» ÇÏ¿© °üÂûÇØº¸¸é À̸¥¹Ù ¡°¹«¸®Áø À§Ãà(grouped atrophy)¡±ÀÌ ³ªÅ¸³ª¼­, ´Ù¸¥ º´ÅÍ¿¡ ÀÇÇÑ °Í°ú °¨º°ÀÌ °¡´ÉÇÏ´Ù.
¿µ¹® smooth muscle ÇÑ±Û ¹Î¹«´Ì±ÙÀ°, ÆòȰ±ÙÀ°
¼³¸í   
  ±ÙÀ° Áß¿¡¼­ °¡·Î¹«´Ì°¡ ¾ø´Â ±Ù. °¡·Î¹«´Ì±Ù¿¡ ´ëÀÀµÇ´Â ¸»ÀÌ´Ù. Ã´Ãßµ¿¹°¿¡¼­´Â ½ÉÀå±Ù ÀÌ¿ÜÀÇ ³»Àå±ÙÀº ¸ðµÎ°¡ ¹Î¹«´Ì±ÙÀÌ´Ù. ¸¹Àº ³»ÀåÀå±âÀÇ º®¿¡ ºÐÆ÷µÇ¾î ÀÖÀ¸¸ç, ´ë°³ µ¹¸²Ãþ°ú ¼¼·ÎÃþÀÇ µÎ ÃþÀ¸·Î ¹è¿­µÇ¾î ÀÖ´Ù. ¼ÒÈ­°üÀ̳ª ¿ä°ü °°Àº °ü¸ð¾çÀÇ ±¸Á¶¿¡¼­´Â ²ÞƲ¿îµ¿À» ÀÏÀ¸ÄÑ ³»¿ë¹°ÀÌ ¾Æ·¡·Î ³»·Á°¡°Ô Çϴ ÀÛ¿ëÀ» ÇÑ´Ù. Ç×¹®°ü, À§, ¿äµµ µî¿¡¼­´Â µ¹¸²ÃþÀÇ ±ÙÀ°À̠ƯÈ÷ µÎ²¨¿öÁ® ³»¿ë¹°ÀÌ ³»·Á°¡´Â °ÍÀ» Á¶ÀýÇϴ Á¶ÀÓ±ÙÀ°ÀÌ Çü¼ºµÇ¾î ÀÖ´Ù. Ç÷°ü¿¡´Â µ¹¸²Ãþ¸¸ ÀÖÀ¸¸ç, Ç÷°üÀ» ¼öÃàÇÏ¿© Ç÷¾×À» Áã¾îÂ¥´Â ÀÛ¿ëÀ» ÇÑ´Ù. ¶ÇÇÑ ÀÚÀ²½Å°æÀÇ Áö¹è¸¦ ¹ÞÀ¸¸ç, ¿ì¸®ÀÇ ÀÇÁö¿Í °ü°è¾øÀÌ ÀÛ¿ëÇÑ´Ù.
¿µ¹® voluntary muscle ÇÑ±Û ¼öÀDZÙ
¼³¸í   
  ÀÇÁöÀÇ ÈûÀ¸·Î ¿òÁ÷ÀÏ ¼ö Àִ ±ÙÀ°. °ñ°Ý±Ù ¿Ü¿¡ ÇǺΠ³»ÀÇ ÇDZÙ, °üÀýÁÖ¸Ó´Ï¿¡ ºÎÂøÇϰí Àִ °üÀý±Ù µîÀÌ ¿©±â¿¡ ¼ÓÇÑ´Ù. ¼öÀDZÙÀÇ ±Ù¼¶À¯¿¡´Â °¡·Î¹«´Ì°¡ ÀÖÀ¸¹Ç·Î °¡·Î¹«´Ì±ÙÀ̶ó°íµµ Çϳª, ½ÉÀå±ÙÀº °¡·Î ¹«´Ì°¡ À־ ¼öÀDZÙÀÌ ¾Æ´Ï¹Ç·Î ¼öÀDZٰú °¡·Î¹«´Ì±ÙÀº µ¿ÀǾî´Â ¾Æ´Ï´Ù. ¼öÀDZÙÀÇ ¿îµ¿Àº ¹Î¹«´Ì±Ùº¸´Ù ºü¸£´Ù. ¼öÀDZÙÀ̶ó Çصµ °ñ°Ý±Ù µîÀº ±ÙÀ°¹«¸®·Î¼­ ¿òÁ÷ÀÏ ¼ö ÀÖÀ¸³ª, °³°³ÀÇ ±ÙÀ°Àº µû·Îµû·Î ¸¶À½´ë·Î ¿òÁ÷À̰ԠÇÒ ¼ö ¾ø´Ù. ±Ó¹ÙÄû±ÙÀ°Àº »ç¶÷ÀÇ °æ¿ì ¹ßÀ°ÀÌ ³ªºü ¸¶À½´ë·Î ¿òÁ÷À̰ԠÇÏ±â ¾î·Æ´Ù. 
¿µ¹® facial muscle ÇÑ±Û ¾ó±¼±ÙÀ°
¼³¸í   
  ¾ó±¼ÀÇ ÇǺθ¦ ¿òÁ÷À̰í ÀÌ¿¡ ºÎÂøµÇ¾î Àִ ¾ó±¼½Å°æÀÇ °ø±ÞÀ» ¹Þ´Â ¼ö¸¹Àº ±ÙÀ°À» Æ÷ÇÔÇϴ ¾ó±¼Ç¥Á¤±ÙÀ̳ª ¸ð¹æ±Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-double stranded deoxyribonucleic acid antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • anti-dsDNA antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antimitochondrial antibody
    Ç×¹ÌÅäÄܵ帮¾ÆÇ×ü, Ç׻縳üÇ×ü
  • antineutrophil cytoplasmic antibody
    Ç×Áß¼º±¸¼¼Æ÷ÁúÇ×ü
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • muscle disease
    ±ÙÀ°º´
  • muscle flap
    ±ÙÀ°ÆÇ, ±ÙÆÇ
  • red muscle fiber
    Àû»ö±ÙÀ°¼¶À¯, Àû»ö±ÙÀ°¼¼Æ÷
  • smooth muscle fiber
    ¹Î¹«´Ì±ÙÀ°¼¶À¯, ¹Î¹«´Ì±ÙÀ°¼¼Æ÷
  • white muscle fiber
    ¹é»ö±ÙÀ°¼¶À¯, ¹é»ö±ÙÀ°¼¼Æ÷
  • muscle
    ±ÙÀ°
  • abdominal muscle
    ¹è±ÙÀ°, º¹±Ù
  • facial muscle
    ¾ó±¼±ÙÀ°
  • gastrocnemius muscle
    ÀåµýÁö±Ù
  • gluteus muscle
    º¼±â±Ù, µÐ±Ù
  • hamstring muscle
    µÚ³Ò´Ù¸®±Ù
  • iliopsoas muscle
    ¾ûµ¢Ç㸮±Ù
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody feedback mechanism
    Ç×üµÇ¸ÔÀÓ±âÀü
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • atypical antibody
    ÀÌÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • FTA (fluorescent treponemal antibody)
    ¸Åµ¶Çü±¤Ç×ü °Ë»ç¹ý
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gp 120/160 antibody
    Gp 120/160 Ç×ü
  • Gp 24 antibody
    Gp 24 Ç×ü
  • I antibody
    I Ç×ü
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
  • Jo-1 antibody
    Jo-1 Ç×ü
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • Lewis antibody
    ·çÀ̽ºÇ×ü
  • Lutheran antibody
    ·çÅ×¶õÇ×ü
  • M2 antibody
    M2 Çü Ç×ü
  • P antibody
    P Ç×ü
  • Scl-70 antibody
    Scl-70 Ç×ü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lateral lumbar intertransverse muscle<³ª> muscle intertransversarii laterales lu mborum
    ¿ÜÃø¿ä±Ø°£±Ù.
  • latissimus dorsi muscle ; muscle latissimus dorsi
    ±¤¹è±Ù.
  • least abductor muscle of little toe<³ª> muscle abductor digiti minimi
    ¼ÒÁö ¿ÜÀü±Ù.
  • least abductor muscle of little toe<³ª> muscle abductor digiti minimi
    ¼ÒÁö¿ÜÀü±Ù.
  • lesser psoas muscle ; muscle psoas minor
    ¼Ò ¿ä ±Ù(á³é¦ÐÉ).
  • lesser psoas muscle ; muscle psoas minor
    ¼Ò¿ä±Ù.
  • levator muscle of upper lip ; muscle levator labii superioris
    »ó¼ø°Å±Ù<¾È¿ÍÇϱÙ>.
  • levator muscle of upper lip =muscle levator labii
    »ó¼ø°Å±Ù
  • lip, levator muscle of upper =muscle levator labi
    »ó¼ø°Å±Ù
  • long extensor muscle of great toe ³ª muscle extensor hallucis longus
    Àå ¹«Áö ½Å±Ù.
  • long extensor muscle of thumb ³ª muscle extensor pollicis longus
    Àå ¸ðÁö ½Å±Ù.
  • long extensor muscle of toes ³ª muscle extensor digitorum longus
    Àå Áö ½Å±Ù.
  • long flexor muscle of great toe ³ª muscle flexor hallucis longus
    Àå ¹«Áö±¼±Ù.
  • long flexor muscle of thumb ³ª muscle flexor pollicis longus
    Àå ¸ðÁö ±¼±Ù.
  • long flexor muscle of toes ³ª muscle flexor digitorum longus
    Àå Áö±¼ ±Ù.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Obliquus auricularis muscle
    ±Ó¹ÙÄûºø±Ù
    [¿¾ ¿ë¾î] À̰³»ç±Ù
  • Auricular pyramidal muscle
    ±Ó¹ÙÄûÇǶó¹Ô±Ù
    [¿¾ ¿ë¾î] À̰³Ãßü±Ù
  • Muscle fascicle
    ±ÙÀ°´Ù¹ß
    [¿¾ ¿ë¾î] ±Ù¼Ó
  • Muscle fiber
    ±ÙÀ°¼¶À¯
    [¿¾ ¿ë¾î] ±Ù¼¶À¯
  • Satellite cell of skeletal muscle
    ±ÙÀ°À§¼º¼¼Æ÷
    [¿¾ ¿ë¾î] ±ÙÀ§¼º¼¼Æ÷
  • Muscle layer
    ±ÙÀ°Ãþ
    [¿¾ ¿ë¾î] ±ÙÃþ
  • Tracheal muscle
    ±â°ü±Ù
    [¿¾ ¿ë¾î] ±â°ü±Ù
  • Bronchial muscle
    ±â°üÁö±Ù
    [¿¾ ¿ë¾î] ±â°üÁö±Ù
  • Bronchoesophageal muscle
    ±â°üÁö½Äµµ±Ù
    [¿¾ ¿ë¾î] ±â°üÁö½Äµµ±Ù
  • Sulcus for flexor hallucis longus muscle
    ±ä¾öÁö±ÁÈû±ÙÈûÁÙ°í¶û
    [¿¾ ¿ë¾î] Àå¸ðÁö±¼±Ù°Ç±¸
  • Sulcus for peroneus longus muscle
    ±äÁ¾¾Æ¸®±ÙÈûÁÙ°í¶û
    [¿¾ ¿ë¾î] Àåºñ°ñ±Ù°Ç±¸
  • Bipennate muscle
    ±ê±ÙÀ°
    [¿¾ ¿ë¾î] ¿ì»ó±Ù
  • Deep transverse perineal muscle
    ±íÀº»ô°¡·Î±Ù
    [¿¾ ¿ë¾î] ½ÉȸÀ½È¾±Ù
  • Coccygeus muscle
    ²¿¸®±Ù
    [¿¾ ¿ë¾î] ¹Ì°ñ±Ù
  • Spiral muscle
    ³ª¼±±Ù
    [¿¾ ¿ë¾î] ³ª¼±±Ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody formation
    Ç×ü Çü¼º(ù÷ô÷û¡à÷)
  • antibody heterogeneity
    Ç×ü ºÒ±ÕÀϼº(ù÷ô÷ÝÕгìéàõ)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • antibody response
    Ç×ü ´ëÀÀ(ù÷ô÷Óßëë)
  • antibody specificity
    Ç×ü ƯÀ̼º(ù÷ô÷÷åì¶àõ)
  • antibody titer
    Ç×ü¿ª°¡(ù÷ô÷æ³Ê¤)
  • antibody valence
    Ç×ü°¡(ù÷ô÷ʤ)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
  • anticomplement fluorescent antibody technique
    Ç׺¸Ã¼ Çü±¤Ç×ü¼ú(ù÷ÜÍô÷û«ÎÃù÷ô÷âú)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • bifunctional antibody
    ¾ç±â´É Ç×ü(å»Ñ¦Òö ù÷ô÷)
  • bispecific antibody
    ¾çƯÀ̼º Ç×ü(å»÷åì¶àõù÷ô÷)
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • iliocostal muscle
    Àå°ñ´Á°ñ±Ù, Àå´Á±Ù
  • iliopsoas muscle
    Àå°ñÇ㸮±Ù, Àå¿ä±Ù
  • inferior rectus muscle
    ÇÏÁ÷±Ù
  • intercostal muscle
    ´Á°£±Ù
  • internal obturator muscle
    ³»Æó¼â±Ù
  • laryngeal muscle
    ÈĵαÙ
  • lateral pterygoid muscle
    ¿ÜÃøÀ͵¹±Ù
  • lateral rectus muscle
    ¿ÜÁ÷±Ù
  • levator muscle
    °Å±Ù
  • levator veli palatini muscle
    ±¸°³°Å±Ù
  • long head of biceps muscle of thigh
    ´ëÅðÀ̵αÙÀåµÎ
  • longus capitis muscle
    µÎÀå±Ù
  • masticatory muscle
    ÀúÀÛ±Ù, ±³±Ù
  • medial rectus muscle
    ³»Ãø°ðÀº±Ù, ³»Á÷±Ù
  • muscle
    ±ÙÀ°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ASM acid sphingomyelinase; airway smooth muscle; American Society for Microbiology; anterior scalenus mu...
CM California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ...
LM lactic acid mineral [medium]; lactose malabsorption; laryngeal mask; laryngeal muscle; lateral malle...
MG Marcus Gunn [pupil]; margin; medial gastrocnemius [muscle]; membranous glomerulonephritis; menopausa...
MS Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ASMC aortic smooth muscle cell
AMA Arm Muscle Area
AMC Arm muscle circumference
BSM Bronchial smooth muscle
CM Circular muscle
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • antiglobulin antibody
    Çױ۷κθ° Ç×ü
  • antiinsulin antibody
    Ç×Àν¶¸° Ç×ü
  • antinuclear antibody
    Ç×ÇÙ Ç×ü
    ÇÙ Ç׿ø¿¡ ´ëÇÑ Ç×ü·Î¼­ º¸Åë Àü½Å¼º È«¹Ý¼º ³¶Ã¢À» °¡Áø ȯÀÚÀÇ Ç÷û¿¡¼­ ¹ß°ßµÈ´Ù. ±×·¯³ª ·ù¸¶Æ¼¼º °üÀý¿°, °øÇÇÁõ ±×¸®°í ´Ù¸¥ °áÇÕÁ¶Á÷Àå¾Ö ȯÀÚ¿¡¼­µµ ¹ß°ßµÈ´Ù.
  • antiphospholipid antibody
    Ç×ÀÎÁöÁú Ç×ü
  • antiplatelet antibody
    Ç×Ç÷¼ÒÆÇ Ç×ü
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cellular antibody
    ¼¼Æ÷ Ç×ü
    ƯÀÌÀûÀÎ ¾Æ¹Ì³ë»ê ¹è¿­À» °¡Áø ¼¼Æ÷¼º ¸é¿ª ±Û·ÎºÒ¸° ºÐÀÚ.
  • circulating antibasement membrane antibody
    ¼øÈ¯ Ç×±âÀú¸· Ç×ü
  • cold reacting antibody
    ÇÑ·© Ç×ü
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
antinuclear antibody <immunology> Antinuclear antibody is an antibody that react against components of the cell nucleus such as DNA, RNA, histone or non-histone proteins.
These antibodies are present in a variety of immunologic or autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis and in persons taking hydralazine, procainamide or isoniazid.
A serologic measurement for antinuclear antibodies can aid in the diagnosis of unexplained arthritis, rashes or chest pains.
Acronym: ANA
(12 Jan 1998)
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á